Compare Enveric Biosciences Inc (ENVB) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Prospect Capital Corporation — how do they compare? Enveric Biosciences Inc trades at $1.55 (market cap $6.20M), while Prospect Capital Corporation trades at $2.29 (market cap $1.15B). The key difference: Prospect Capital Corporation is far larger — about 185.5× Enveric Biosciences Inc's market cap, and Prospect Capital Corporation pays a 21.83% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | PSEC | |
|---|---|---|
Market Cap | $6.20M | $1.15B |
Sector | Health | Financials |
52-Week High | $17.40 | $3.05 |
52-Week Low | $1.27 | $2.11 |
Enterprise Value | $1.30M | — |
Dividend Yield | — | 21.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
PSEC trades at $2.33, up 5.43% in the last session, with a neutral technical signal and bearish moving averages. The company shows mixed fundamentals, with a low P/B of 0.4 and recent quarterly EPS beats, but negative revenue and net income in 2025. Recent news highlights a dividend increase for an affiliate fund and the sale of Valley Electric for a 4.8x return.
Outlook is cautious; the stock offers value with a low P/B and dividend yield, but significant risks include persistent negative profitability, high P/S ratio, and analyst skepticism. Investment appeal hinges on portfolio turnaround and sustained dividend stability amid operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
